Distinct pattern of TP53 mutations in human immunodeficiency virus–related head and neck squamous cell carcinoma

Cancer

Volumn 124, Issue 1, 2018, Pages 84-94

  Gleber Netto, Frederico O ^a   Zhao, Mei ^a   Trivedi, Sanchit ^a   Wang, Jiping ^a   Jasser, Samar ^a   McDowell, Christina ^a   Kadara, Humam ^a,f   Zhang, Jiexin ^a   Wang, Jing ^a   William, William N ^a   Lee, J Jack ^a   Nguyen, Minh Ly ^b   Pai, Sara I ^c   Walline, Heather M ^d   Shin, Dong M ^b   Ferris, Robert L ^e   Carey, Thomas E ^d   Myers, Jeffrey N ^a   Pickering, Curtis R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

head and neck cancer; human immunodeficiency virus (HIV); human papillomavirus (HPV); mutation; TP53 gene

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; HLA A ANTIGEN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; PROTEIN P16; PROTEIN P53; AJUBA PROTEIN, HUMAN; CADHERIN; CASP8 PROTEIN, HUMAN; CASPASE 8; CCND1 PROTEIN, HUMAN; CDKN2A PROTEIN, HUMAN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2C; EGFR PROTEIN, HUMAN; F BOX/WD REPEAT CONTAINING PROTEIN 7; FAT1 PROTEIN, HUMAN; FBXW7 PROTEIN, HUMAN; HRAS PROTEIN, HUMAN; KEAP1 PROTEIN, HUMAN; LIM PROTEIN; NFE2L2 PROTEIN, HUMAN; NOTCH1 PROTEIN, HUMAN; NOTCH2 PROTEIN, HUMAN; NSD1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P21; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TP53 PROTEIN, HUMAN; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; AJUBA GENE; ARTICLE; CASP8 GENE; CCND1 GENE; CDKN2A GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA LIBRARY; DNA SEQUENCE; EGFR GENE; EXON; FAT1 GENE; FBXW7 GENE; FEMALE; GENE; GENE MUTATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HLA A GENE; HRAS GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KEAP1 GENE; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; NFE2L2 GENE; NONHUMAN; NOTCH1 GENE; NOTCH2 GENE; NSD1 GENE; NUCLEIC ACID BASE SUBSTITUTION; PIK3CA GENE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SOFTWARE; TGFBR2 GENE; TP53 GENE; TP63 GENE; WART VIRUS; CASE CONTROL STUDY; COMPLICATION; GENETICS; HEAD AND NECK TUMOR; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; CADHERINS; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CASPASE 8; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P18; F-BOX-WD REPEAT-CONTAINING PROTEIN 7; FEMALE; HEAD AND NECK NEOPLASMS; HIV INFECTIONS; HLA-A ANTIGENS; HUMANS; IN SITU HYBRIDIZATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; LIM DOMAIN PROTEINS; MALE; MIDDLE AGED; NF-E2-RELATED FACTOR 2; NUCLEAR PROTEINS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, NOTCH1; RECEPTOR, NOTCH2; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 85031709519     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.31063     Document Type: Article

References (48)

1. Grulich AE, Van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59-67.
2. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148:728-736.
3. Lin CS, Lin C, Weng SF, Lin SW, Lin YS. Cancer survival in patients with HIV/AIDS in the era of highly active antiretroviral therapy in Taiwan: a population-based cohort study. Cancer Epidemiol. 2013;37:719-724.
4. Brickman C, Palefsky JM. Cancer in the HIV-infected host: epidemiology and pathogenesis in the antiretroviral era. Curr HIV/AIDS Rep. 2015;12:388-396.
5. Gritz ER, Vidrine DJ, Lazev AB, Amick BC, Arduino RC. Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res. 2004;6:71-77.
6. Mdodo R, Frazier EL, Dube SR, et al. Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. Ann Intern Med. 2015;162:335-344.
7. Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus–positive women. J Natl Cancer Inst. 2005;97:577-586.
8. Xi LF, Koutsky LA, Castle PE, et al. Relationship between cigarette smoking and human papilloma virus types 16 and 18 DNA load. Cancer Epidemiol Biomarkers Prev. 2009;18:3490-3496.
9. Schabath MB, Villa LL, Lazcano-Ponce E, Salmeron J, Quiterio M, Giuliano AR. Smoking and human papillomavirus (HPV) infection in the HPV in Men (HIM) study. Cancer Epidemiol Biomarkers Prev. 2012;21:102-110.
10. Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe. 2014;15:266-282.
11. De Martel C, Shiels MS, Franceschi S, et al. Cancers attributable to infections among adults with HIV in the United States. AIDS. 2015;29:2173-2181.
12. Engsig FN, Gerstoft J, Kronborg G, et al. Head and neck cancer in HIV patients and their parents: a Danish cohort study. Clin Epidemiol. 2011;3:217-227.
13. D'Souza G, Carey TE, William WN, et al. Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr. 2014;65:603-610.
14. Helleberg M, Gerstoft J, Afzal S, et al. Risk of cancer among HIV-infected individuals compared to the background population: impact of smoking and HIV. AIDS. 2014;28:1499-1508.
15. Singh B, Balwally AN, Shaha AR, Rosenfeld RM, Har-El G, Lucente FE. Upper aerodigestive tract squamous cell carcinoma. The human immunodeficiency virus connection. Arch Otolaryngol Head Neck Surg. 1996;122:639-643.
16. Powles T, Powles J, Nelson M, et al. Head and neck cancer in patients with human immunodeficiency virus-1 infection: incidence, outcome and association with Epstein-Barr virus. J Laryngol Otol. 2004;118:207-212.
17. Walline HM, Carey TE, Goudsmit CM, et al. High-risk HPV, biomarkers, and outcome in matched cohorts of head and neck cancer patients positive and negative for HIV. Mol Cancer Res. 2016;15:179-188.
18. Mourad WF, Hu KS, Shasha D, et al. Long-term outcome of seropositive HIV patients with head and neck squamous cell carcinoma treated with radiation therapy and chemotherapy. Anticancer Res. 2013;33:5511-5516.
19. McLemore MS, Haigentz M, Smith RV, et al. Head and neck squamous cell carcinomas in HIV-positive patients: a preliminary investigation of viral associations. Head Neck Pathol. 2010;4:97-105.
20. Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333:1154-1157.
21. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333:1157-1160.
22. Lawrence MS, Sougnez C, Lichtenstein L, et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576-582.
23. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356:1944-1956.
24. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357:2552-2561.
25. Neskey DM, Osman AA, Ow TJ, et al. Evolutionary action score of TP53 identifies high-risk mutations associated with decreased survival and increased distant metastases in head and neck cancer. Cancer Res. 2015;75:1527-1536.
26. Baylor College of Medicine. EAp53 server. http://mammoth.bcm.tmc.edu/cgi-bin/panos/EAp53.cgi. Accessed June 1, 2016.
27. Picard A, Badoual C, Hourseau M, et al. HPV prevalence in HIV patients with head and neck squamous cell carcinoma. AIDS. 2016;30:1257-1266.
28. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11:781-789.
29. Souza RP, Gimenes F, De Abreu AL, et al. Differences in the mutation of the p53 gene in exons 6 and 7 in cervical samples from HIV- and HPV-infected women. Infect Agent Cancer. 2013;8:38.
30. Zhou G, Wang J, Zhao M, et al. Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. Mol Cell. 2014;54:960-974.
31. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002;21:7435-7451.
32. Pickering CR, Zhang J, Neskey DM, et al. Squamous cell carcinoma of the oral tongue in young non-smokers is genomically similar to tumors in older smokers. Clin Cancer Res. 2014;20:3842-3848.
33. Hayes DN, Van Waes C, Seiwert TY. Genetic landscape of human papillomavirus–associated head and neck cancer and comparison to tobacco-related tumors. J Clin Oncol. 2015;33:3227-3234.
34. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003;424:99-103.
35. Harris RS, Bishop KN, Sheehy AM, et al. DNA deamination mediates innate immunity to retroviral infection. Cell. 2003;113:803-809.
36. Bishop KN, Holmes RK, Sheehy AM, Malim MH. APOBEC-mediated editing of viral RNA. Science. 2004;305:645.
37. Matsumoto Y, Marusawa H, Kinoshita K, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med. 2007;13:470-476.
38. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-421.
39. Burns MB, Lackey L, Carpenter MA, et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 2013;494:366-370.
40. Lindley RA. The importance of codon context for understanding the Ig-like somatic hypermutation strand-biased patterns in TP53 mutations in breast cancer. Cancer Genet. 2013;206:222-226.
41. Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus–driven tumor development. Cell Rep. 2014;7:1833-1841.
42. Izumi T, Io K, Matsui M, et al. HIV-1 viral infectivity factor interacts with TP53 to induce G2 cell cycle arrest and positively regulate viral replication. Proc Natl Acad Sci U S A. 2010;107:20798-20803.
43. Sato Y, Tsurumi T. Genome guardian p53 and viral infections. Rev Med Virol. 2013;23:213-220.
44. Verma S, Ali A, Arora S, Banerjea AC. Inhibition of β-TrcP dependent ubiquitination of p53 by HIV-1 Vpu promotes p53 mediated apoptosis in human T cells. Blood. 2011;117:6600-6608.
45. Greenway AL, McPhee DA, Allen K, et al. Human immunodeficiency virus type 1 Nef binds to tumor suppressor p53 and protects cells against p53-mediated apoptosis. J Virol. 2002;76:2692-2702.
46. Kim RH, Yochim JM, Kang MK, Shin KH, Christensen R, Park NH. HIV-1 Tat enhances replicative potential of human oral keratinocytes harboring HPV-16 genome. Int J Oncol. 2008;33:777-782.
47. Qureshi MN, Barr CE, Hewlitt I, et al. Detection of HIV in oral mucosal cells. Oral Dis. 1997;3(suppl 1):S73-S78.
48. Moore JS, Rahemtulla F, Kent LW, et al. Oral epithelial cells are susceptible to cell-free and cell-associated HIV-1 infection in vitro. Virology. 2003;313:343-353.